177 related articles for article (PubMed ID: 26819726)
1. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports.
Kato Y; Umetsu R; Abe J; Ueda N; Nakayama Y; Kinosada Y; Nakamura M
J Pharm Health Care Sci; 2015; 1():15. PubMed ID: 26819726
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of voluntary reporting of adverse drug events related to antipsychotics in Australia: 14-year analysis.
Khalil H; Hoppe D; Ameen N
Ther Adv Drug Saf; 2021; 12():20420986211012854. PubMed ID: 34104400
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Kimura G; Kadoyama K; Brown JB; Nakamura T; Miki I; Nisiguchi K; Sakaeda T; Okuno Y
Int J Med Sci; 2015; 12(2):135-40. PubMed ID: 25589889
[TBL] [Abstract][Full Text] [Related]
5. Differences in Antipsychotic-Related Adverse Events in Adult, Pediatric, and Geriatric Populations.
Sagreiya H; Chen YR; Kumarasamy NA; Ponnusamy K; Chen D; Das AK
Cureus; 2017 Feb; 9(2):e1059. PubMed ID: 28465867
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
7. Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.
Uwai Y; Nabekura T
Pharmazie; 2022 Sep; 77(7):255-261. PubMed ID: 36199180
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis.
Baker RA; Pikalov A; Tran QV; Kremenets T; Arani RB; Doraiswamy PM
Psychopharmacol Bull; 2009; 42(1):11-31. PubMed ID: 19204649
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics.
Evoy KE; Teng C; Encarnacion VG; Frescas B; Hakim J; Saklad S; Frei CR
Subst Abuse; 2019; 13():1178221819844205. PubMed ID: 31068753
[TBL] [Abstract][Full Text] [Related]
10. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Stahl SM; Grady MM
Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
[TBL] [Abstract][Full Text] [Related]
11. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Tada M; Shirakawa K; Matsuoka N; Mutoh S
Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
15. Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Dias Alves M; Micoulaud-Franchi JA; Simon N; Vion-Dury J
J Clin Psychopharmacol; 2018 Dec; 38(6):555-562. PubMed ID: 30247179
[TBL] [Abstract][Full Text] [Related]
16. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database.
Anzai T; Takahashi K; Watanabe M
Psychiatry Clin Neurosci; 2019 Jan; 73(1):27-33. PubMed ID: 30375086
[TBL] [Abstract][Full Text] [Related]
17. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
